Acquired by ARRINEX, INC. has been acquired by Stryker, which suggests the ClariFix technology is now under a larger medical devices umbrella. This creates potential cross-sell opportunities with Stryker’s existing product lines and sales channels.

Chronic Rhinitis Leader ClariFix is FDA-cleared for adults with Chronic Rhinitis and represents a first-in-class, minimally invasive neural pathway interruption therapy. This positions the company’s technology as a premier option to ENT practices seeking durable relief, signaling strong upsell potential to clinics adopting innovativeRhinitis treatments.

Silicon Valley Presence Headquartered in Menlo Park with a Silicon Valley pedigree, Arrinex demonstrates a tech-forward approach and proximity to leading healthcare innovators, offering collaboration possibilities with high-tech medical centers and academic medical groups for trials, training, and joint development.

Growth Signals Revenue is modest but the acquisition by a major OEM (Stryker) implies validated market potential and integration opportunities within a broader product ecosystem, suggesting levers for expanded disposables, service agreements, and training programs.

Engagement & Support With a relatively small employee base and a niche product, there is a clear opportunity to target clinics and hospital systems with turnkey adoption support, including training, installation, and post-sale support for ClariFix devices and related cryotherapy services.